Irish Jian 4

What Happened Jian Irish, President and Chief Executive Officer of Metagenomi Therapeutics, was granted awards on April 1, 2026: 46,000 restricted stock units (RSUs) and 276,000 derivative awards (reported as a derivative grant). Both grants show an acquisition price of $0.00 (typical for compensation grants). No cash purchase or sale occurred.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (file appears timely).
• Grants: 46,000 RSUs (F1) and 276,000 derivative awards (reported as derivative; F4 describes option-like vesting).
• Price: $0.00 per share (compensation award).
• Vesting (per footnotes):
  • RSUs (F1): 25% vest on June 5, 2027; remaining 75% vest in 12 equal quarterly installments thereafter, subject to continued service.
  • Derivative/option-style award (F4): 25% vest on April 1, 2027; remainder vests in 36 equal monthly installments, subject to continued service.
• Shares held in trusts (F2, F3) are noted; the reporting person disclaims beneficial ownership of those trusts' shares except to the extent of any pecuniary interest.
• Form does not specify total shares owned by the reporting person after these grants in this report.

Context These entries are grants of equity compensation (RSUs and a derivative/option-style award) and are routine for executives; they are not open-market purchases or sales. Vesting is time‑based and contingent on continued service, so the economic or voting rights typically only arise as portions vest. Trust-held shares noted in the filing are reported separately and do not necessarily indicate direct beneficial ownership by the insider.